Supplemental figure 5.
Prognostic value of CIP2A in advanced human breast cancer patient material and characterization of vinorelbine effects. A) Among patients with either axillary node–positive breast cancer or otherwise high-risk node-negative cancer (FinHer study), women with CIP2A-positive breast cancer tended to have less favorable survival compared to those with CIP2A-negative cancer p=0.073 by univariate Cox proportional hazards model. B) Effect of CIP2A expression on the survival free of a distant recurrence or death of Her2 negative breast cancer. p=0.024 by univariate Cox proportional hazards model. C) In subset analyses stratified by presence of tumor HER2 amplification, CIP2A expression was not associated with survival in HER2-positive cancers p=0.687 by univariate Cox proportional hazards model. D) CIP2A expression does not correlate with survival of docetaxel + FEC treated HER2-negative patients. P=0.373 by log-rank test. E,F) Vinorelbine does not induce p21 expression with concentration of 20 nM that efficiently inhibits CIP2A (E) and E2F1 (F) expression 24h after treatment in MCF-7 cells.